Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...

San Francisco will follow vaccine recommendations from a coalition of western states as upheaval continues with federal ...

A Florida pharmacy licensing board on Tuesday made clear that prescriptions aren’t necessary for  patients who want to get ...

Moderna said today its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, as well as in individuals aged 12 to 64 with at least one underlying risk ...

The protein-based vaccine now covers the LP.8.1 variant and can be given to adolescents aged 12 years or older who previously ...

People are still debating whether the mRNA from COVID-19 vaccines remains in the body longer than it should. Some say it ...

Moderna's 2025-2026 mNEXSPIKE showed strong immune response and safety in Phase 4 trials, reinforcing FDA approval for the LP.8.1-targeting formula.

Here’s a look at what we know about where to get the shot in Oregon, who can get it — and what's happening with state and ...

Moderna has early in-human data showing its next-generation COVID-19 vaccine, mNEXSPIKE, has the potential to offer strong immune protection against the latest rapidly spreading SARS-CoV-2 virus.

Moderna (MRNA) stock is in focus as its updated mNEXSPIKE COVID vaccine boosts antibodies 15-fold on average against the new ...

Moderna (MRNA) announced preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE, which targets the LP.8.1 variant of SARS-CoV-2 to ...

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups ...